Jan 16, 2024 / 09:30PM GMT
Operator
Thank you for standing by, and welcome to the REGENXBIO interim data update from Phase II AAVIATE trial of ABBV-RGX-314 for treatment of wet AMD using suprachoroidal delivery Hawaiian Eye and Retina 2024 Conference Call. (Operator Instructions)
As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Mr. Ken Mills, President and CEO of REGENXBIO. Please go ahead, sir.
Ken Mills REGENXBIO Inc.-President&CEO
Welcome, everyone, to our Hawaiian Eye and Retina event. I am Ken Mills, CEO of REGENXBIO, and I'm pleased to introduce our agenda and make some opening remarks.
In November, REGENXBIO announced the pipeline prioritization and corporate restructuring plan that will enable us to focus our capabilities and resources on large commercial opportunities where our product candidates are differentiated, can be expedited, and support meaningful value generation soon and for the long term. Our highest priority programs are ABBV-RGX-314 for the treatment of retinal
Regenxbio Inc Interim Data Update Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
